Background-Vascular complications after transfemoral transcatheter aortic valve replacement are common and associated with significant morbidity and mortality. Little is known about the effect of access approach on vascular complications.
V ascular complications are a significant cause of morbidity and mortality after transcatheter aortic valve replacement (TAVR) via the transfemoral approach. Experience from the United States and European trials using sheaths with outer diameters of 8.3 to 9.2 mm (24-26 F) in concert with the first-generation balloon-expandable Edwards Sapien aortic bioprosthesis (Edwards Inc, Irvine, CA) demonstrated a 20% to 30% rate of total vascular complications, which included hematomas, retroperitoneal hemorrhage, and iliofemoral dissection among others. [1] [2] [3] [4] [5] These vascular complications were independently associated with mortality. 3 Lower rates of vascular complications have been observed with the use of smaller diameter sheaths in concert with the secondgeneration balloon-expandable Sapien XT valve and the self-expanding CoreValve Revalving System (Medtronic, Inc, Minneapolis, MN). 2, 6, 7 
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Transfemoral TAVR is performed via both open surgical (OS) cutdown and fully percutaneous (PC) approaches. 8, 9 Little is known about differences in vascular outcomes between the 2 approaches. In addition, it is widely assumed that postprocedural length of stay is positively affected by the use of the PC approach, but no analysis to date has demonstrated an independent association between the 2. In this study, we sought to characterize and compare vascular complications and postprocedural length of stay in patients undergoing transfemoral TAVR via both the OS and PC approaches. We further analyzed these differences over time and with a variety of sheath sizes to determine predictors of complications.
Methods

Patient Population
Between 2007 and 2013, 331 patients underwent transfemoral TAVR with the Edwards Sapien or Edwards Sapien XT valve at the Hospital of the University of Pennsylvania. This included patients enrolled in the Placement of Transcatheter Valve (PARTNER) 1 and 2 trials, 4,10 patients who received a valve through the PARTNER continued access program, and patients who received a valve for Food and Drug Adminstrationapproved commercial indications. The current study was approved by the Institutional Review Board of the University of Pennsylvania.
All patients undergoing transfemoral TAVR at our institution formed the cohort for this analysis. These patients met criteria for TAVR with all having severe aortic stenosis (aortic valve area of <0.8 cm 2 ; mean gradient, >40 mm Hg, or peak aortic jet velocity of ≥4.0 m/s). All patients were inoperable, high risk, or intermediate risk for surgical aortic valve replacement. These criteria have been described previously. 4, 10 Major exclusion criteria included low Society of Thoracic Surgeons (STS) risk score (except in patients deemed inoperable for other reasons, such as porcelain aorta, substernal left internal mammary artery graft, and cirrhosis) and the use of transapical or direct aortic access because of poor iliofemoral access for transfemoral TAVR.
End Points
Vascular end points were defined according to Valve Academic Research Consortium-2 definitions. 11 Vascular complications were assessed at 30 days after procedure. Any vascular complication that occurred between the procedure and the 30-day follow-up visit was included in the analysis.
Data Collection
Detailed chart reviews were conducted to identify patient demographics, preoperative patient characteristics, and clinical presentation. Patients were assessed at baseline and at a 30-day postprocedure visit. Operative reports and 30-day visits were reviewed to obtain information about sheath size/type, device type, and procedural complications. Hospitalization records and discharge summaries were used to obtain information on the patient's clinical course after procedure, including in-hospital postprocedure complications.
Vascular Access Evaluation, Procedure, and Closure
Vascular access before the procedure was evaluated using multiple modalities. Most patients underwent invasive contrast-based descending aortography with iliofemoral run-off using a 5F marker pigtail (Merit Medical Systems, Inc, South Jordan, UT). Quantitative vascular analysis was performed to calculate minimal artery diameters (MAD) in the iliofemoral circulation. A total of 321 patients (97%) also underwent imaging of their iliofemoral vessels with multidetector computed tomography. These multidetector computed tomography studies were postprocessed with axial centerline reconstruction using M2S (M2S, West Lebanon, NH), which was then also used to determine MAD. M2S calculations of MAD were preferentially used over angiographic determination when available. 12, 13 The side for TAVR sheath access was chosen preprocedure based on the judgment of a multidisciplinary TAVR team. This decision was predicated on MAD, vessel tortuosity, and calcification. The preprocedure aortogram was additionally used to identify the appropriate location over the femoral head to access the common femoral artery in PC cases. When additional information was needed about the location of the common femoral artery in PC cases, a crossover angiogram of the iliofemoral vessels was performed from the contralateral side at the outset of the case to guide appropriate access. All procedures were done under general anesthesia. All patients received heparin during the procedure to achieve an activated clotting time of >250 s. At the conclusion of the procedure on closure of the arteriotomy site, 25 to 50 mg of protamine was administered to reverse the anticoagulation and assist with hemostasis. In patients undergoing percutaneous access, arterial closure was performed using the preclose technique with 2 to 3 Perclose Proglide devices (Abbott Vascular Inc, Redwood City, CA). 14 In most PC cases, a slightly undersized peripheral angioplasty balloon was inflated to 1 atmosphere in the external iliac artery for 5 to 10 minutes to assist with achievement of hemostasis. Contralateral iliofemoral angiography was performed after closure to confirm vessel integrity and assess for the presence of vascular complications. In patients undergoing OS access, the arteriotomy site was closed surgically with crossover angiography performed to evaluate for vascular complications.
Statistical Analysis
Continuous variables were compared between 2 groups using the unpaired t test and the Mann-Whitney test was used to compare nonnormally distributed continuous variables. Categorical variables were compared using the χ 2 test and Fisher exact test. Patients were also stratified by the first and second half of our experience, as well as tertiles of our experience, and these analyses were repeated.
Multivariable analysis for vascular outcomes was performed using a Cox regression, adjusting for sex, STS score, difference between sheath outer diameter and minimal artery diameter (ShOD-MAD) in millimeters, and mode of access (OS or PC). A P value of <0.05 (2-tailed) was considered to be statistically significant. Adjusting for ShOD-MAD allowed us to account for the different sheath sizes used throughout the study. In addition, to best control for the nonrandom assignment of patients to 1 of 2 access approaches, we created propensity-matched cohorts of patients after constructing logistic-regression models that predicted the likelihood of OS access based on sex, STS score, body mass index, left or right access, and ShOD-MAD. This analysis resulted in 112 matched pairs. We then assessed differences in vascular complications, in-hospital mortality, and length of stay in these 2 groups. All statistical analyses were performed with SAS version 9 (SAS Institute Inc, Cary, NC).
Results
Baseline Characteristics
During the study period, 120 patients underwent transfemoral TAVR via the OS and 211 patients via the PC approach.
WHAT IS KNOWN
• Vascular complications after transfemoral transcatheter aortic valve replacement are common and are associated with significant morbidity and mortality.
• Transfemoral transcatheter aortic valve replacement can be successfully performed via both the open and the percutaneous approaches.
• There are limited data on the relationship between access approach and vascular complications after transfemoral transcatheter aortic valve replacement.
WHAT THE STUDY ADDS
• There is a similar risk of vascular complications but significantly lower postprocedural length of stay with the percutaneous approach to transfemoral transcatheter aortic valve replacement when compared with the open approach.
• The degree of sheath oversizing is associated with vascular complications regardless of access approach.
There was no statistically significant difference in age and sex between the OS and PC groups. There was a greater incidence of cardiovascular comorbidities in the OS group when compared with those in the PC group, including coronary artery disease (74% versus 51%; P<0.001), previous myocardial infarction (29% versus 18%; P=0.03), chronic kidney disease (36% versus 17%; P<0.001), and peripheral vascular disease (58% versus 24%; P<0.001). OS patients were more likely to have class III or IV New York Heart Association functional class (94% versus 80%; P<0.001) and higher STS score (11.1 versus 9.1; P=0.007) than PC patients. Average sheath outer diameter was slightly higher in the OS group when compared with that in the PC group (8.6 versus 8.4 mm; P<0.001; Table 1 ).
Unadjusted Analyses
In unadjusted analyses of the PC group, those who experienced vascular complications were more likely to be women (74% versus 47%; P=0.005) and have minimal artery diameter<sheath outer diameter (67% versus 54%;
P=0.02). Length of stay after procedure in PC patients was significantly less in patients who did not experience vascular complications (7.2 versus 9.2 days; P=0.02; Table 2 ). When OS and PC patients were combined into 1 group, there was no statistically significant difference in in-hospital mortality or length of stay between the 2 groups ( Table I in the Data  Supplement) .
When all patients were divided into tertiles based on the percentage difference between ShOD-MAD and MAD (ShOD-MAD/MAD also known as the percent sheath oversize), there was a statistically significant difference in overall and major vascular complications in each tertile. Length of stay also increased with increasing tertiles (Figure) .
The most common vascular complications in both groups were iliofemoral dissection and iliofemoral femoral perforation/vascular damage. There were 7 patients in the percutaneous group who had a failure of percutaneous access and required conversion to an OS approach ( Table II in 
Multivariable Analysis
Multivariable regression analysis of all patients demonstrated that women were more likely to experience overall vascular complications (odds ratio [OR], 2.2; 95% confidence interval [CI], 1.1-4.3; P=0.02). Larger differences between sheath outer diameter and MAD were more likely to be associated with overall vascular complications (OR, 1.4 for every 1 mm increase in ShOD-MAD; 95% CI, 1.1-1.8; P=0.02) and major vascular complication (OR, 2.0 for every 1 mm increase ShOD-MAD; 95% CI, 1.4-2.9; P<0.001).
The effect of STS score on overall vascular complications was an OR 1.06 for every 1% increase in STS score (95% CI, 0.99-1.13; P=0.09) and on major vascular complications was an OR 1.05 for every 1% increase in STS score (95% CI, 0.99-1.12; P=0.12).
Before Propensity Matching
Before propensity matching, there were more major vascular complications in the OS group when compared with those in the PC group (20% versus 11%; P=0.03). There was a nearly significant increase in greater overall vascular complications in the OS group when compared with those in the PC group (26% versus 17%; P=0.06). Length of stay after procedure was greater in the OS group than in the PC group (9.9 versus 7.5 days; P=0.003). There was no statistically significant difference in all-cause in-hospital mortality between the 2 groups (Tables 3 and 4; Table III in the Data Supplement). There were no statistically significant differences in vascular complications, length of stay, or mortality between the OS and the PC groups over time ( Table IV in 
After Propensity Matching
Propensity-matched analysis revealed no difference in overall or major vascular complications between the OS and the PC groups. However, postprocedure length of stay was significantly reduced in the PC group (7.9 versus 10.0 days; P=0.04; Table 4 ).
Discussion
In this study of 331 patients undergoing transfemoral TAVR via either an OS or PC approach, we observed a significantly shorter postprocedure length of stay in PC patients. The PC technique was not associated with reduced vascular complications. Higher rates of vascular complications in all patients, regardless of access type, were associated with female sex and the degree of sheath oversizing with respect to the minimal artery diameter (ShOD-MAD).
Toggweiler et al 6 described a cohort of 130 consecutive transfemoral TAVR cases performed via the PC approach. In unadjusted analyses, they described improving rates of vascular complications over time. No comparisons with OS patients were performed. More recently, 2 studies have compared PC with OS patients. A randomized trial of 30 patients did not find differences in vascular complications between the 2 approaches. Although it confirmed the feasibility of the PC approach, this study was underpowered to evaluate the end point of vascular outcomes. 15 An additional recent analysis showed unadjusted decreased length of stay in PC patients when compared with that in OS patients, but adjusted analyses of vascular outcomes and length of stay were not performed. 16 The largest study to date is based on the Pooled-Rotterdam-Milano-Toulouse in Collaboration (PRAGMATIC) initiative at 5 European centers. They examined 986 patients undergoing transfemoral TAVR via both OS and PC approaches. They also found no difference in vascular complications in OS and PC approaches using a multivariable logistic-regression model. They did not have data on length of stay and did not incorporate second-generation sheath sizes. 17 In contrast to the current analysis, no previous study has examined the association of the PC and OS approaches with vascular complications in a wide cross section of patient risk groups with the full range of sheath sizes currently being used in the United States. In addition, no other study has incorporated robust statistical adjustment with propensity-matched analysis to assess outcomes between the 2 groups.
We found that the most important predictor of vascular complications was not access strategy or sheath size itself but rather the relationship between minimal artery diameter and sheath outer diameter. The individual relationship of sheath size to a patient's minimal artery diameter was associated with complications in a graded fashion. Those in the highest tertile of percent sheath oversize with an average of 20% oversize of the sheath when compared with the MAD had almost a 30% rate of vascular complications. Conversely, in the lowest tertile, patients with an average 14% undersize of the sheath when compared with the MAD, there were far fewer vascular complications (8%). The association of vascular complications with respect to vessel caliber has been suggested in 2 previous analyses. 6, 18 However, the current study is the first to demonstrate increasing risk of harm with increasing sheath oversizing when accounting for the minimal luminal diameter of the entire iliofemoral segment traversed by the sheath. Naturally, with technological improvements, sheath size will continue to decrease making vascular access complications with transfemoral TAVR less common overall. However in the individual patient, even with reduced sheath sizes, our results indicate that careful preprocedure planning with respect to the relationship between ShOD and MAD will continue to be warranted because this proves to be the strongest predictor of vascular complications. In addition, vigilant surveillance, including crossover angiography at the conclusion of the case, may be indicated to assure vascular complications are not missed after the case in patients with high ShOD-MAD.
In our multivariable analysis, we also noted that female sex was an independent predictor of vascular complications, even when controlled for differences in comorbidities and ShOD-MAD. This has been suggested in previous studies, 17, 19, 20 but ours is the first to note this finding with adjustment for sheath and artery sizes. The reason for these differences is unknown but has also been noted in literature about other endovascular catheter-based procedures 21, 22 and may be because of differences in vessel characteristics, tortuosity, and calcification, as well as smaller body size of female patients. Of note, the increased risk of female sex on vascular complications was only noted in percutaneous patients and not in OS patients. This raises the possibility that an OS approach may be preferred in women. Additional work is needed to understand these differences better. Importantly, other potentially clinically relevant factors, such as age or comorbidities as represented by the STS score, did not correlate with vascular complications.
Our propensity-matched analysis revealed that the OS approach is independently associated with longer length of stay than the PC approach, despite no differences in vascular complications. This may because of the increased recovery time and time to ambulation after a surgical cutdown and closure as opposed to percutaneous closure. In addition, in our PC patients, we found that the occurrence of a vascular complication was associated with a longer length of stay. A PC approach seems to be preferable from both an economic and a patient comfort perspective; however, additional study is necessary to assess whether reduced length of stay after PC TAVR is associated with decreased costs and increased patient satisfaction.
Despite an improvement in operator experience and valve technology during the course of this study, we did not observe an improvement in vascular complications over time in either the OS or the PC groups. We did observe that, over time, the mean difference in sheath outer diameter and minimal artery diameter in our patient population did not change significantly (−0.17 to 0.18 mm; P=0.10). Thus, despite smaller sheaths, the lack of change in vascular complications over time may be explained by our institution offering transfemoral TAVR to patients with smaller vessels and thus similar ShOD-MAD differences when compared with our initial cases.
We did not adjust for some anatomic characteristics, such as tortuosity and calcification in our study. The absence of information on vessel calcification and tortuosity is a limitation of the present study because these factors can affect the risk of vascular complications during the procedure. 18 Additional studies will benefit from including these characteristics. There is also a theoretical potential for bias in the choice of transfemoral approach based on these characteristics. However, at our institution, a decision was made after our early open experience to move entirely to a percutaneous approach. Thus, after a certain point, every candidate felt suitable for transfemoral access that was operated on via a PC approach, minimizing this potential bias.
An OS approach has often been advocated as a preferred approach because of presumed better control of bleeding and vascular complications. Using a propensity-matched analysis, our study questions this notion and also shows a lower length of stay in PC patients. Although our conclusions are drawn from a large data set and patient experience with advanced statistical modeling, our conclusions are not based on randomized trial data and our findings underscore the need for a multicenter, randomized clinical trial to assess these 2 approaches better, to confirm the generalizability of our findings to other centers and populations, and to unmask other potential independent determinants of vascular complications. We are not aware of any current plans to organize such an effort.
Despite being the largest US analysis of PC versus OS patients and the only analysis to use advanced statistical modeling, including propensity matching, our study has limitations. The study is a retrospective analysis and the conclusions are not based on randomized clinical trial data. Hence, the influence of unmeasured confounders on our analysis cannot be ruled out. Most patients early in our experience were performed via OS access and those later in our experience were entirely PC access. Because patients earlier in the experience were at higher risk, there is a difference in baseline characteristics, which we attempted to adjust for with propensitymatched analysis. In addition, propensity-matched analysis adjusts for but does not control for nonrandom assignments to treatment. Although the majority of vascular complications occur at the time of the procedure, our analysis is limited by not having longer term outcomes. We did not collect some procedural characteristics, such as contrast usage and procedure length, that may differ between OS and PC approaches. In addition, this is a single-center US study and experiences may differ in other institutions and countries.
Conclusions
Transfemoral TAVR can be performed via the PC route with similar risk of vascular complications and briefer postprocedural length of stay than the OS route. Women are at higher risk of vascular complications after transfemoral TAVR. Increasing degrees of sheath oversizing, especially ShOD-MAD/MAD >10%, are associated with significantly higher rates of vascular complications and longer length of stay. The relationship between ShOD and MAD should be carefully noted when planning the transfemoral approach for TAVR, independent of the OS or PC approach.
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